What question did this study set out to answer?

This review aims to summarize advancements in managing pediatric inflammatory bowel disease through biologic and small-molecule therapies.

January 22, 2026PharmaceuticalsOpen Access

Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules

View Full Paper

Ask AI

Bookmark

Authors

BMB. Mucci EPElisabetta Palazzolo FRFlaminia Ruberti

Discussion

Member takes

Overview

Narrative review summarizes efficacy and safety of biologics and small molecules in pediatric inflammatory bowel disease, suggesting new therapeutic options.

Key Points

This review aims to summarize advancements in managing pediatric inflammatory bowel disease through biologic and small-molecule therapies.
Literature search conducted across PubMed, Embase, and Cochrane Library.
Focused on studies published in the last five years.
Data retrieved from guidelines and position papers from relevant organizations.
Anti-TNF agents infliximab and adalimumab are effective for remission induction and maintenance.
New biologics like vedolizumab and ustekinumab show promise for patients not responding to anti-TNF treatment.
Emerging small molecules such as JAK inhibitors and S1P modulators provide rapid, oral treatment options.
The gut microbiome is noted as a potential therapeutic target influencing treatment efficacy.

Cite This Study

Mucci et al. (2026) studied this question.

synapsesocial.com/papers/6971be50642b1836717e2fa2 https://doi.org/10.3390/ph19010176

View Full Paper

Ask AI

Bookmark

January 22, 2026PharmaceuticalsOpen Access

Advances in the Management of Pediatric Inflammatory Bowel Disease: From Biologics to Small Molecules

View Full Paper

Ask AI

Bookmark

Authors

BMB. Mucci EPElisabetta Palazzolo FRFlaminia Ruberti

Discussion

Member takes

Overview

Narrative review summarizes efficacy and safety of biologics and small molecules in pediatric inflammatory bowel disease, suggesting new therapeutic options.

Key Points

This review aims to summarize advancements in managing pediatric inflammatory bowel disease through biologic and small-molecule therapies.
Literature search conducted across PubMed, Embase, and Cochrane Library.
Focused on studies published in the last five years.
Data retrieved from guidelines and position papers from relevant organizations.
Anti-TNF agents infliximab and adalimumab are effective for remission induction and maintenance.
New biologics like vedolizumab and ustekinumab show promise for patients not responding to anti-TNF treatment.
Emerging small molecules such as JAK inhibitors and S1P modulators provide rapid, oral treatment options.
The gut microbiome is noted as a potential therapeutic target influencing treatment efficacy.

Cite This Study

Mucci et al. (2026) studied this question.

synapsesocial.com/papers/6971be50642b1836717e2fa2 https://doi.org/10.3390/ph19010176

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

View Full Paper

Ask AI

Bookmark